Citius Oncology Reports $0.34 Loss Per Share for Fiscal Year Ending September 30
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 23 2025
0mins
Should l Buy CTOR?
Source: Yahoo Finance
- Financial Performance: Citius Oncology reported a diluted loss of $0.34 per share for the fiscal year ending September 30, indicating ongoing investments in R&D and operations, yet highlighting the need for improved profitability to attract investor interest despite market challenges.
- Market Reaction: The loss exceeding market expectations may lead to decreased investor confidence, potentially negatively impacting the company's stock price and prompting management to reassess its financial strategy to enhance future performance.
- R&D Expenditure: The company continues to increase its spending on R&D, which, while not translating into profits in the short term, could yield significant market opportunities and revenue growth if successful product development occurs in the long run.
- Strategic Adjustments: Citius Oncology may need to revise its business model and market strategies to address current financial challenges and achieve sustainable growth, ensuring competitiveness in the highly competitive biopharmaceutical industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CTOR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CTOR
About CTOR
Citius Oncology, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapies. The Company’s lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the diphtheria toxin (DT) fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
LYMPHIR Shows Promise in Gynecologic Cancer Treatment
- Clinical Trial Results: The Phase 1 trial led by the University of Pittsburgh demonstrated that LYMPHIR combined with KEYTRUDA showed no unexpected safety signals in 25 patients, indicating a favorable safety profile that could offer new treatment options for difficult-to-treat gynecologic cancers.
- Efficacy Assessment: Among 21 evaluable patients, the combination therapy achieved a 24% objective response rate (ORR) and a 48% clinical benefit rate (CBR), highlighting the potential of this combination to enhance anti-tumor activity and warranting further investigation.
- Market Potential: LYMPHIR is estimated to have a market potential exceeding $400 million, and as demand for novel therapies increases, Citius Oncology's competitive positioning in oncology will be further strengthened, particularly in the ovarian cancer sector where immunotherapy has had limited impact.
- Future Research Plans: Citius Oncology intends to explore the efficacy of LYMPHIR in subsequent Phase 2 studies, and if results are confirmed, it could provide a transformative treatment option for gynecologic cancer patients, significantly improving patient outcomes.
See More
Citius Oncology Reports Positive Phase 1 Trial Results for LYMPHIR in DLBCL
- Clinical Trial Response Rate: The LYMPHIR clinical trial conducted at the University of Minnesota and City of Hope demonstrated an 86% overall response rate, including a 57% complete response and a 29% partial response, indicating the potential efficacy of LYMPHIR in patients with high-risk relapsed DLBCL, which may provide new treatment options in the future.
- Good Safety Profile: LYMPHIR exhibited a favorable safety profile in the trial, with no dose-limiting toxicities observed, laying a solid foundation for its clinical application and potentially enhancing patient acceptance and adherence to treatment.
- Enhancing CAR-T Therapy: The use of LYMPHIR aims to augment the anti-tumor activity of CAR-T cell therapies by improving T-cell depleting effects, which could increase the effectiveness of existing treatment regimens and advance the field of tumor immunotherapy.
- Future Research Directions: The findings set the stage for larger clinical trials, with Citius Oncology planning to further explore the combination of LYMPHIR with other therapies to enhance treatment efficacy and improve long-term patient outcomes.
See More
Citius Oncology Reports Positive Phase 1 Trial Results for LYMPHIR in DLBCL
- Trial Results: The investigator-initiated study of LYMPHIR™ (E7777) at the University of Minnesota and City of Hope demonstrated an overall response rate (ORR) of 86%, including 57% complete responses (CR) and 29% partial responses (PR), indicating its potential efficacy in high-risk relapsed or refractory diffuse large B-cell lymphoma (DLBCL) patients.
- Safety Profile: LYMPHIR was well tolerated in the trial, with no dose-limiting toxicities (DLTs) observed, as all 14 patients completed treatment and proceeded to CAR-T infusion, highlighting its favorable safety profile without any Grade ≥3 immune adverse events reported.
- Treg Depletion Effect: A single dose of LYMPHIR resulted in Treg depletion in nearly all patients, with a median reduction of 24 Tregs/µL, suggesting its potential to enhance standard lymphodepletion regimens and improve the anti-tumor activity of CAR-T therapies.
- Future Research Directions: These findings set the stage for larger studies to assess the potential of LYMPHIR to enhance CAR-T efficacy through prolonged use, further advancing Citius Oncology's strategic positioning in the field of cancer immunotherapy.
See More
Citius Pharmaceuticals Reports $3.9 Million Revenue in Q1 2026
- Revenue Milestone: Citius Pharmaceuticals successfully launched LYMPHIR in December 2025, generating $3.9 million in revenue during Q1 2026, marking a significant transition to a revenue-generating company and reflecting initial success in the cutaneous T-cell lymphoma treatment market.
- Market Potential Assessment: The initial market for LYMPHIR is estimated to exceed $400 million and is underserved by existing therapies, highlighting strategic opportunities and growth potential for Citius in the oncology treatment sector.
- Pipeline Progress: Citius's late-stage pipeline includes Mino-Lok and Halo-Lido, with the former completing a pivotal Phase 3 trial in 2023 and meeting primary and secondary endpoints, which is expected to further drive future revenue growth for the company.
- Financial Stewardship Commitment: The company is committed to financial stewardship to sustain growth momentum while focusing on advancing its late-stage pipeline, aiming to maximize long-term shareholder value through the provision of first-in-class critical care products.
See More
Citius Oncology Reports $3.9 Million in Initial Sales Revenue
- Initial Sales Revenue: Citius Oncology successfully launched LYMPHIR in December 2025, generating $3.9 million in initial sales revenue, marking a pivotal transition from a development-stage organization to a commercial entity, which is expected to significantly enhance future market share and investor confidence.
- Significant Market Potential: The market for LYMPHIR, targeting relapsed or refractory Stage I-III CTCL, is estimated to exceed $400 million and remains underserved by existing therapies, indicating a strategic positioning for long-term growth in the oncology treatment landscape.
- Accelerating Physician Adoption: Since the beginning of 2026, physicians have started initiating patients on LYMPHIR, with the company focusing on accelerating adoption rates and expanding patient access, which will directly drive sales growth and enhance competitive positioning in the market.
- Strategic Investment and Execution: Citius Oncology plans to leverage an advanced AI-enabled commercial platform to support market penetration, with management emphasizing ongoing capital management and evaluation of strategic opportunities to enhance long-term shareholder value, ensuring the company maintains a competitive edge in a rapidly evolving market.
See More
Oncolytics Biotech Inc. Reports 33% Response Rate for Pelareorep in Colorectal Cancer
- Market Potential: The global cancer drugs market is projected to reach $594.3 billion by 2035, with high-tech immunotherapies replacing traditional chemotherapy, positioning Oncolytics Biotech Inc. as a key player in this transformation.
- Clinical Data Breakthrough: Oncolytics' pelareorep achieved a 33% objective response rate in second-line KRAS-mutant microsatellite-stable metastatic colorectal cancer patients when combined with standard chemotherapy, significantly surpassing the historical 6-11% response rate for chemotherapy alone, potentially driving growth in a $20 billion market.
- Enhanced Expert Validation: Oncolytics expanded its Gastrointestinal Tumor Scientific Advisory Board with three globally recognized experts, further elevating the academic validation and industry attention for pelareorep, which may attract more investment and collaboration opportunities.
- Successful FDA Alignment: Oncolytics has secured FDA alignment on its Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, marking the launch of the only immunotherapy registration trial planned for this disease, thereby enhancing its market competitiveness.
See More
LYMPHIR Shows Promise in Gynecologic Cancer Treatment
- Clinical Trial Results: The Phase 1 trial led by the University of Pittsburgh demonstrated that LYMPHIR combined with KEYTRUDA showed no unexpected safety signals in 25 patients, indicating a favorable safety profile that could offer new treatment options for difficult-to-treat gynecologic cancers.
- Efficacy Assessment: Among 21 evaluable patients, the combination therapy achieved a 24% objective response rate (ORR) and a 48% clinical benefit rate (CBR), highlighting the potential of this combination to enhance anti-tumor activity and warranting further investigation.
- Market Potential: LYMPHIR is estimated to have a market potential exceeding $400 million, and as demand for novel therapies increases, Citius Oncology's competitive positioning in oncology will be further strengthened, particularly in the ovarian cancer sector where immunotherapy has had limited impact.
- Future Research Plans: Citius Oncology intends to explore the efficacy of LYMPHIR in subsequent Phase 2 studies, and if results are confirmed, it could provide a transformative treatment option for gynecologic cancer patients, significantly improving patient outcomes.
See More
Citius Oncology Reports Positive Phase 1 Trial Results for LYMPHIR in DLBCL
- Clinical Trial Response Rate: The LYMPHIR clinical trial conducted at the University of Minnesota and City of Hope demonstrated an 86% overall response rate, including a 57% complete response and a 29% partial response, indicating the potential efficacy of LYMPHIR in patients with high-risk relapsed DLBCL, which may provide new treatment options in the future.
- Good Safety Profile: LYMPHIR exhibited a favorable safety profile in the trial, with no dose-limiting toxicities observed, laying a solid foundation for its clinical application and potentially enhancing patient acceptance and adherence to treatment.
- Enhancing CAR-T Therapy: The use of LYMPHIR aims to augment the anti-tumor activity of CAR-T cell therapies by improving T-cell depleting effects, which could increase the effectiveness of existing treatment regimens and advance the field of tumor immunotherapy.
- Future Research Directions: The findings set the stage for larger clinical trials, with Citius Oncology planning to further explore the combination of LYMPHIR with other therapies to enhance treatment efficacy and improve long-term patient outcomes.
See More
Citius Oncology Reports Positive Phase 1 Trial Results for LYMPHIR in DLBCL
- Trial Results: The investigator-initiated study of LYMPHIR™ (E7777) at the University of Minnesota and City of Hope demonstrated an overall response rate (ORR) of 86%, including 57% complete responses (CR) and 29% partial responses (PR), indicating its potential efficacy in high-risk relapsed or refractory diffuse large B-cell lymphoma (DLBCL) patients.
- Safety Profile: LYMPHIR was well tolerated in the trial, with no dose-limiting toxicities (DLTs) observed, as all 14 patients completed treatment and proceeded to CAR-T infusion, highlighting its favorable safety profile without any Grade ≥3 immune adverse events reported.
- Treg Depletion Effect: A single dose of LYMPHIR resulted in Treg depletion in nearly all patients, with a median reduction of 24 Tregs/µL, suggesting its potential to enhance standard lymphodepletion regimens and improve the anti-tumor activity of CAR-T therapies.
- Future Research Directions: These findings set the stage for larger studies to assess the potential of LYMPHIR to enhance CAR-T efficacy through prolonged use, further advancing Citius Oncology's strategic positioning in the field of cancer immunotherapy.
See More
Citius Pharmaceuticals Reports $3.9 Million Revenue in Q1 2026
- Revenue Milestone: Citius Pharmaceuticals successfully launched LYMPHIR in December 2025, generating $3.9 million in revenue during Q1 2026, marking a significant transition to a revenue-generating company and reflecting initial success in the cutaneous T-cell lymphoma treatment market.
- Market Potential Assessment: The initial market for LYMPHIR is estimated to exceed $400 million and is underserved by existing therapies, highlighting strategic opportunities and growth potential for Citius in the oncology treatment sector.
- Pipeline Progress: Citius's late-stage pipeline includes Mino-Lok and Halo-Lido, with the former completing a pivotal Phase 3 trial in 2023 and meeting primary and secondary endpoints, which is expected to further drive future revenue growth for the company.
- Financial Stewardship Commitment: The company is committed to financial stewardship to sustain growth momentum while focusing on advancing its late-stage pipeline, aiming to maximize long-term shareholder value through the provision of first-in-class critical care products.
See More
Citius Oncology Reports $3.9 Million in Initial Sales Revenue
- Initial Sales Revenue: Citius Oncology successfully launched LYMPHIR in December 2025, generating $3.9 million in initial sales revenue, marking a pivotal transition from a development-stage organization to a commercial entity, which is expected to significantly enhance future market share and investor confidence.
- Significant Market Potential: The market for LYMPHIR, targeting relapsed or refractory Stage I-III CTCL, is estimated to exceed $400 million and remains underserved by existing therapies, indicating a strategic positioning for long-term growth in the oncology treatment landscape.
- Accelerating Physician Adoption: Since the beginning of 2026, physicians have started initiating patients on LYMPHIR, with the company focusing on accelerating adoption rates and expanding patient access, which will directly drive sales growth and enhance competitive positioning in the market.
- Strategic Investment and Execution: Citius Oncology plans to leverage an advanced AI-enabled commercial platform to support market penetration, with management emphasizing ongoing capital management and evaluation of strategic opportunities to enhance long-term shareholder value, ensuring the company maintains a competitive edge in a rapidly evolving market.
See More
Oncolytics Biotech Inc. Reports 33% Response Rate for Pelareorep in Colorectal Cancer
- Market Potential: The global cancer drugs market is projected to reach $594.3 billion by 2035, with high-tech immunotherapies replacing traditional chemotherapy, positioning Oncolytics Biotech Inc. as a key player in this transformation.
- Clinical Data Breakthrough: Oncolytics' pelareorep achieved a 33% objective response rate in second-line KRAS-mutant microsatellite-stable metastatic colorectal cancer patients when combined with standard chemotherapy, significantly surpassing the historical 6-11% response rate for chemotherapy alone, potentially driving growth in a $20 billion market.
- Enhanced Expert Validation: Oncolytics expanded its Gastrointestinal Tumor Scientific Advisory Board with three globally recognized experts, further elevating the academic validation and industry attention for pelareorep, which may attract more investment and collaboration opportunities.
- Successful FDA Alignment: Oncolytics has secured FDA alignment on its Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, marking the launch of the only immunotherapy registration trial planned for this disease, thereby enhancing its market competitiveness.
See More
